| Prev Close | 5.62 |
| Open | 5.59 |
| Day Low/High | 5.40 / 5.69 |
| 52 Wk Low/High | 0.34 / 51.60 |
| Volume | 509.64K |
| Avg Volume | 6.40M |
Latest News
Interesting NVAX Put And Call Options For March 15th
Investors in Novavax, Inc. saw new options begin trading this week, for the March 15th expiration.
Interesting NVAX Put And Call Options For February 15th
Investors in Novavax, Inc. saw new options begin trading this week, for the February 15th expiration.
First Week Of July 2019 Options Trading For Novavax (NVAX)
Investors in Novavax, Inc. saw new options become available this week, for the July 2019 expiration.
NVAX: Insiders Vs. Shorts
The most recent short interest data was recently released for the 10/15/2018 settlement date, and Novavax, Inc. is one of the most shorted stocks of the Russell 3000, based on 8.21 "days to cover" versus the median component at 4.82.
First Week Of December 21st Options Trading For Novavax (NVAX)
Investors in Novavax, Inc. saw new options become available this week, for the December 21st expiration.
First Week Of November 16th Options Trading For Novavax (NVAX)
Investors in Novavax, Inc. saw new options become available this week, for the November 16th expiration.
NVAX: Insiders Vs. Shorts
The most recent short interest data was recently released for the 07/13/2018 settlement date, and Novavax, Inc. is one of the most shorted stocks of the Russell 3000, based on 18.69 "days to cover" versus the median component at 6.06.
First Week of NVAX October 19th Options Trading
Investors in Novavax, Inc. saw new options become available this week, for the October 19th expiration.
First Week of March 16th Options Trading For Novavax (NVAX)
Investors in Novavax, Inc. saw new options become available this week, for the March 16th expiration.
Insiders Were Right: NVAX Makes New 52-Week High
In trading on Wednesday, shares of Novavax, Inc. touched a new 52-week high of $1.98/share.
Novavax' Preclinical Influenza Nanoparticle Study Published In Vaccine
Novel vaccine candidate, NanoFlu™, outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study
Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite
Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.
